Page 24 - Latest Updates on Q4 Results

SBI Q4 results preview: Profit may drop up to 12% on treasury loss

SBI Q4FY26 preview: Profit may fall up to 12% due to weak treasury income. Brokerages share NII, loan growth, NIM and dividend expectations

Coforge zooms 10% on solid Q4 show; analysts see up to 47% upside

Elara Capital has upgraded its rating to 'Accumulate' from 'Reduce', while Choice Institutional Equities has reaffirmed its 'Buy' rating following the Q4 results

Q4 results: Bajaj Auto, Paytm, Meesho, Polycab India, 58 more on May 6

Q4FY26 company results: Firms including Shree Cements, Godrej Consumer Products, PB Fintech, Blue Star, and Raymond Lifestyle are also to release their January-March earnings today

Swiggy Q4 preview: Loss may narrow YoY, rev to rise 40%; QC growth eyed

Brokerages tracked by Business Standard estimate Swiggy's net loss at an average of ₹857.56 crore year-on-year (Y-o-Y) from a loss of ₹971.66 crore

Stocks to Watch today: Hero MotoCorp, Paytm, L&T, Bajaj Auto, Policybazaar

Stocks to Watch today, Wednesday, May 6, 2026: Vedanta, Zen Tech, Grasim Industries, PNB, and Emcure Pharma are among the top stocks to watch today

L&T Q4FY26 results: Net profit declines 3% to ₹5,325.60 cr; revenue up 11%

L&T posts marginal decline in Q4 profit due to base effect, while revenue grows 11% on strong order inflow; board recommends Rs 38 per share dividend

M&M Q4FY26 results: PAT up 42% on strong momentum across businesses

Mahindra & Mahindra reports a 42% rise in Q4 PAT to Rs 4,668 crore, driven by strong performance in auto, farm and services businesses, alongside steady growth in EVs

PNB Q4 result: Profit rises 14.4% to ₹5,225 crore; asset quality improves

State-owned Punjab National Bank (PNB) on Tuesday reported a 14.4 per cent year-on-year rise in net profit to Rs5,225crore for the three months ended March 2026, driven by higher interest income. The lender had earned a net profit of Rs 4,567 crore in the year-ago period. However, the bank's total income fell to Rs36,319crore during the quarter under review from Rs36,705 crore a year ago, PNB said in a regulatory filing. Interest income grew to Rs32,157crore from Rs31,989crore in the fourth quarter of the previous financial year. On the asset quality front, the bank's gross Non-Performing Assets (NPAs) improved to 2.95 per cent of gross advances as compared to 3.95per cent by the end of March 2025. Similarly, net NPAs came down to 0.29 per cent from 0.4 per cent. The board also recommended a dividend of Rs 3 per equity share for FY 2025-26, subject to approval of shareholders at the ensuing Annual General Meeting of the bank.

Valuations, execution concerns ahead for BHEL despite strong Q4 growth

BHEL's strong Q4FY26 performance and robust order book are offset by concerns over valuations, execution challenges, and sustainability of margin gains

Hero MotoCorp net up 26.1% on GST cuts, broad-based growth in ICE

Hero MotoCorp reports 26.1% rise in Q4FY26 net profit, driven by strong demand, GST rate rationalisation, and growth across domestic and global markets

NSE's Q4 FY26 results: Consolidated PAT rises 8% to ₹2,871 crore

NSE reports 8.3% rise in Q4FY26 consolidated profit to Rs 2,871 crore and sets aside Rs 84 crore provision for pending settlement applications with Sebi

Ajanta Pharma Q4 FY26 results: Net profit rises 18.4% to ₹266.7 crore

Ajanta Pharma Ltd on Tuesday reported a 18.4 per cent rise in consolidated net profit at Rs 266.7 crore in the fourth quarter ended March 31, on the back of strong US generics revenue growth. The company had posted a consolidated net profit of Rs 225.26 crore in the corresponding period previous fiscal, Ajanta Pharma Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 1,421.64 crore as against Rs 1,170.41 crore in the year-ago period, it added. During the quarter branded generics in the markets of India, Asia and Africa clocked a combined revenue of Rs 859 crore as compared to Rs 805 crore in the year-ago period, up 7 per cent. US generic revenue was at Rs 505 crore as compared to Rs 325 crore in the same period a year ago, up 56 per cent, the company said. Total expenses in the fourth quarter were higher at Rs 1,135.96 crore as compared to Rs 919.11 crore in the same period a year ago, the company said. For FY26, consolidated n

Poonawalla Fincorp's Q4FY26 results: Net profit jumps 4x to ₹255 crore

Poonawalla Fincorp reports over fourfold rise in Q4FY26 net profit, supported by strong NII growth and nearly 70% increase in assets under management

Emcure Pharmaceuticals Q4 results: Profit jumps 28%, revenue up by 16%

The rise in profits was attributed to the robust performance in international markets and growth in new launches from Emcure's in-house portfolio

L&T Q4 FY26 results: Net profit dips 3.1% to ₹5,326 crore, new CFO named

BENGALURU, May 5 - India's Larsen & Toubro posted a 3.1% fall in quarterly profit on Tuesday, as the ​Middle East war disrupted he infrastructure giant's ​projects in the region.

Marico Q4FY26 result: Net profit rises 18% to ₹408 crore on strong growth

Its consolidated revenue from operations in the fourth quarter stood at ₹3,333 crore compared to ₹2,730 crore in the year-ago period

Emcure Pharmaceuticals Q4 results: Net profit rises 24% to ₹243.74 crore

Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at Rs 243.74 crore in the fourth quarter ended March 2026 on the back of robust growth in international business. The company had posted a consolidated net profit of Rs 197.24 crore in the corresponding quarter last fiscal, Emcure Pharmaceuticals Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 2,469.7 crore as against Rs 2,116.25 crore in the same period a year ago, it added. International business sales were at Rs 1,493 crore, up 25.7 per cent YoY, with strong growth across markets supported by base business ramp-up and new launches, Emcure Pharma said. On the other hand, domestic business sales were at Rs 977 crore, up 5.2 per cent YoY. Softer performance was largely due to the Zuventus portfolio and team reorganisation, it added. Zuventus is a subsidiary of the company. Total expenses in the fourth quarter were higher at Rs ..

Raymond Q4FY26 result: Net profit falls 53% to ₹11.93 crore; revenue rises

Raymond Ltd on Tuesday reported a 53 cent decline in consolidated net profit from continuing operations at Rs 11.93 crore in the fourth quarter ended March 31, 2026, impacted by an exceptional item outgo. The company had posted a consolidated net profit from continuing operations at Rs 25.42 crore in the corresponding quarter last fiscal, Raymond Ltd said in a regulatory filing. Consolidated revenue from continuing operations in the fourth quarter stood at Rs 602.91 crore as against Rs 557.46 crore in the same period of the previous fiscal year, it added. Total expenses in the quarter under review were higher at Rs 587.14 crore as compared to Rs 556.85 crore in the year-ago period. In the fourth quarter, Raymond Ltd, which is into aerospace, defense, precision technology and auto components, said it had an exceptional item outgo of Rs 20.03 crore. For the fiscal FY26, consolidated net profit from continuing operations was at Rs 53.54 crore as compared to Rs 52.02 crore in FY25, th

Voltamp Transformers hits 20% lower circuit on weak Q4; profit falls 50%

Voltamp Transformers' net profit declined to ₹48 crore from ₹97 crore during the Q4FY25.

Godrej Properties falls 5% despite strong Q4; brokerages see up to 15% gain

Godrej Properties reported a 73 per cent increase in its consolidated profit at ₹650 crore, as compared to ₹376 crore in the year-ago period